Article Text
Statistics from Altmetric.com
In their letter to the editor ‘Discussion of Methotrexate Dosage’, Maguire et al 1 raised three issues regarding our recent paper.2 We appreciate their interest in our study and will address these issues here.
First, regarding the methotrexate dosage, we reiterate what we have discussed in the discussion section of our paper: ‘As in the post-trial follow-up period, the controlled situation was lost and treatment was open to the rheumatologists, long-term outcomes in our study may have been influenced by the use of different antirheumatic drugs’. We did not …
Footnotes
Competing interests JMvL received honoraria from MSD, Roche, Pfizer, BMS, Eli Lilly. JWJB received honoraria from AbbVie, BMS, MSD, Pfizer, Roche, SUN, UCB. MS was supported by a research grant from Astra Zeneca. Astra Zeneca was not involved in this study.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Correspondence